US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CervoMed

7.05

-0.0600-0.84%

Post-market: 7.050.00000.00%16:43 EDT

Volume:60.03K

Turnover:434.08K

Market Cap:65.23M

PE:-2.73

High:7.46

Open:7.14

Low:7.01

Close:7.11

52wk High:16.94

52wk Low:1.80

Shares:9.25M

Float Shares:4.93M

Volume Ratio:1.26

T/O Rate:1.22%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.5788

EPS(LYR):-2.0179

ROE:-54.21%

ROA:-33.63%

PB:1.95

PE(LYR):-3.49

Loading ...

Overview Company News Filings

CervoMed appoints Quigley to board of directors

Press Release: CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley

CervoMed Showcases Neflamapimod’s Phase 2b Progress for Dementia with Lewy Bodies

CervoMed Releases Investor Presentation on Website

CervoMed to Present at the Emerging Growth Conference

CervoMed’s Strategic Phase 3 Trial Plans and Financial Outlook Justify Buy Rating

CervoMed Unveils Promising Phase 2b Trial Results

CervoMed Inc. Files Initial Statement of Beneficial Ownership for Chief Commercial and Business Officer Matthew Winton

BUZZ-U.S. STOCKS ON THE MOVE-Datadog, First Majestic, Best Buy

CervoMed’s Strategic Advancements in Clinical Trials Justify Buy Rating

CervoMed Inc Shares Rise 3.5% After Dementia Drug Shows Promise in Mid-Stage Study

THOMSON REUTERS

BUZZ-U.S. STOCKS ON THE MOVE-Ford Motor, CVS Health, Phillips 66

BUZZ-CervoMed rises after dementia drug shows promise in mid-stage study

CervoMed Inc - Anticipates FDA Feedback on Phase 3 Trial in Q4 2025

THOMSON REUTERS

CervoMed Inc - Significant Reduction in Plasma Gfap Levels Correlated to Treatment

THOMSON REUTERS

CervoMed Inc - Significant Improvement in Cdr-SB in Low Ad Co-Pathology Participants

THOMSON REUTERS

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

CervoMed appoints Matthew Winton as chief commercial, business officer

BRIEF-Cervomed Appoints Matthew Winton, Ph.D., As Chief Commercial And Business Officer

Press Release: CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CRVO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CRVO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CRVO\",,,,,undefined,":{"symbol":"CRVO","market":"US","secType":"STK","nameCN":"CervoMed","latestPrice":7.05,"timestamp":1761940800000,"preClose":7.11,"halted":0,"volume":60033,"hourTrading":{"tag":"盘后","latestPrice":7.05,"preClose":7.05,"latestTime":"16:43 EDT","volume":22,"amount":155.82,"timestamp":1761943426029},"delay":0,"floatShares":4934300,"shares":9252719,"eps":-2.578766,"marketStatus":"Market Closed","change":-0.06,"latestTime":"10-31 16:00:00 EDT","open":7.14,"high":7.4582,"low":7.0071,"amount":434082.233991,"amplitude":0.063446,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.578766,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1762160400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":7.11,"preHourTrading":{"tag":"盘前","latestPrice":7.15,"preClose":7.11,"latestTime":"08:00 EDT","volume":15,"amount":107.25,"timestamp":1761912004963},"postHourTrading":{"tag":"盘后","latestPrice":7.05,"preClose":7.05,"latestTime":"16:43 EDT","volume":22,"amount":155.82,"timestamp":1761943426029},"volumeRatio":1.257188},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CRVO\",,,,,undefined,":{"symbol":"CRVO","floatShares":4934300,"roa":"-33.63%","roe":"-54.21%","lyrEps":-2.017884,"volumeRatio":1.257188,"shares":9252719,"dividePrice":0,"high":7.4582,"amplitude":0.063446,"preClose":7.11,"low":7.0071,"week52Low":1.8,"pbRate":"1.95","psRate":"8.39","week52High":16.94,"institutionHeld":0,"latestPrice":7.05,"eps":-2.578766,"divideRate":0,"volume":60033,"delay":0,"ttmEps":-2.578766,"open":7.14,"prevYearClose":2.34,"prevWeekClose":7.07,"prevMonthClose":8.09,"prevQuarterClose":8.09,"fiveDayClose":7.07,"twentyDayClose":8.7,"sixtyDayClose":9.34},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CRVO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-08","symbol":"CRVO","fiscalQuarterEnding":"2025/06","expectedEps":-0.57,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754625600000,"reportTimeType":"pre","actualEps":-0.7},{"market":"US","date":"2025-05-12","symbol":"CRVO","fiscalQuarterEnding":"2025/03","expectedEps":-0.6,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"pre","actualEps":-0.56},{"market":"US","date":"2025-03-17","symbol":"CRVO","fiscalQuarterEnding":"2024/12","expectedEps":-0.67,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742184000000,"reportTimeType":"pre","actualEps":-0.8},{"market":"US","date":"2024-11-12","symbol":"CRVO","fiscalQuarterEnding":"2024/09","expectedEps":-0.41,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.55},{"date":"2024-08-12","symbol":"CRVO","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2024/06","expectedEps":-0.24,"defaultRemindTime":1723449600000,"name":null,"time":"Pre-Market","dateTimestamp":1723435200000,"actualEps":-0.27}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CRVO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CRVO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.8571,"hold":0.1429,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8571,"analysts":7,"updateTime":1757390400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CRVO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CRVO","date":"2025-10-30","current":-2.733866,"percent":0.877778,"low":-119.682483,"twenty":-38.838654,"median":-7.461209,"eighty":-3.38406,"high":-1.31262,"avg":-22.339169,"sd":25.065096,"marketCap":63658706},"quantilePoints":[{"date":"2023-09-01","current":-5.788607,"twenty":-5.849231,"median":-5.813052,"eighty":-5.769051,"marketCap":33591560},{"date":"2023-09-08","current":-5.135433,"twenty":-5.817941,"median":-5.700604,"eighty":-4.975855,"marketCap":29801161},{"date":"2023-09-15","current":-4.791246,"twenty":-5.769051,"median":-5.182368,"eighty":-4.935961,"marketCap":27803825},{"date":"2023-09-22","current":-4.51746,"twenty":-5.708427,"median":-5.1589,"eighty":-4.822536,"marketCap":26215035},{"date":"2023-09-29","current":-4.66902,"twenty":-5.505043,"median":-5.045475,"eighty":-4.536234,"marketCap":27094543},{"date":"2023-10-06","current":-5.250814,"twenty":-5.262548,"median":-5.040586,"eighty":-4.536234,"marketCap":30470722},{"date":"2023-10-13","current":-6.893527,"twenty":-5.817941,"median":-5.065031,"eighty":-4.595684,"marketCap":40003462},{"date":"2023-10-20","current":-8.995809,"twenty":-6.690143,"median":-5.197035,"eighty":-4.691783,"marketCap":52203100},{"date":"2023-10-27","current":-9.201148,"twenty":-7.153624,"median":-5.22148,"eighty":-4.714546,"marketCap":53394692},{"date":"2023-11-03","current":-8.379791,"twenty":-8.309389,"median":-5.27037,"eighty":-4.77036,"marketCap":48628322},{"date":"2023-11-10","current":-9.709606,"twenty":-8.530373,"median":-5.764162,"eighty":-4.78929,"marketCap":56345302},{"date":"2023-11-17","current":-41.851906,"twenty":-9.287195,"median":-5.866832,"eighty":-4.791246,"marketCap":55950767},{"date":"2023-11-24","current":-43.761983,"twenty":-9.977525,"median":-6.385068,"eighty":-4.83818,"marketCap":58504301},{"date":"2023-12-01","current":-41.597229,"twenty":-22.855354,"median":-7.177091,"eighty":-4.969206,"marketCap":55610296},{"date":"2023-12-08","current":-37.39506,"twenty":-39.737313,"median":-7.68555,"eighty":-5.041564,"marketCap":49992521},{"date":"2023-12-15","current":-37.352614,"twenty":-39.16082,"median":-8.389569,"eighty":-5.054275,"marketCap":49935776},{"date":"2023-12-22","current":-28.736045,"twenty":-38.685423,"median":-8.477572,"eighty":-5.063075,"marketCap":38416500},{"date":"2023-12-29","current":-26.825968,"twenty":-38.401034,"median":-8.868694,"eighty":-5.079111,"marketCap":35862966},{"date":"2024-01-05","current":-39.899383,"twenty":-38.549596,"median":-9.044699,"eighty":-5.121353,"marketCap":53340488},{"date":"2024-01-12","current":-39.88198,"twenty":-39.488419,"median":-9.670494,"eighty":-5.172981,"marketCap":53317222},{"date":"2024-01-19","current":-38.625999,"twenty":-39.313626,"median":-10.04206,"eighty":-5.199968,"marketCap":51638132},{"date":"2024-01-26","current":-38.965567,"twenty":-39.313626,"median":-10.775414,"eighty":-5.223436,"marketCap":52092093},{"date":"2024-02-02","current":-34.593614,"twenty":-39.237223,"median":-27.727949,"eighty":-5.242992,"marketCap":46247338},{"date":"2024-02-09","current":-43.719537,"twenty":-39.237223,"median":-28.736045,"eighty":-5.262548,"marketCap":58447556},{"date":"2024-02-16","current":-68.677874,"twenty":-39.888941,"median":-31.961952,"eighty":-5.505043,"marketCap":91813733},{"date":"2024-02-23","current":-59.169936,"twenty":-40.466999,"median":-34.275268,"eighty":-5.692782,"marketCap":79102808},{"date":"2024-03-01","current":-63.372175,"twenty":-41.597229,"median":-35.401364,"eighty":-5.759273,"marketCap":84720676},{"date":"2024-03-08","current":-73.849585,"twenty":-41.945287,"median":-36.142899,"eighty":-5.808163,"marketCap":98727664},{"date":"2024-03-15","current":-76.245081,"twenty":-43.210183,"median":-36.501144,"eighty":-5.849231,"marketCap":101930142},{"date":"2024-03-22","current":-103.758666,"twenty":-50.901256,"median":-37.320992,"eighty":-6.027192,"marketCap":138712367},{"date":"2024-03-28","current":-90.558053,"twenty":-57.709789,"median":-37.373837,"eighty":-6.291199,"marketCap":121064797},{"date":"2024-04-05","current":-61.481111,"twenty":-59.566286,"median":-37.479952,"eighty":-6.48676,"marketCap":133529165},{"date":"2024-04-12","current":-71.595379,"twenty":-59.997513,"median":-38.212361,"eighty":-6.942417,"marketCap":155496070},{"date":"2024-04-19","current":-71.737433,"twenty":-62.930842,"median":-38.413768,"eighty":-7.153624,"marketCap":155804594},{"date":"2024-04-26","current":-94.969175,"twenty":-65.856384,"median":-38.647222,"eighty":-7.237715,"marketCap":206260987},{"date":"2024-05-03","current":-91.738931,"twenty":-67.584491,"median":-38.965567,"eighty":-7.396119,"marketCap":199245307},{"date":"2024-05-10","current":-90.826862,"twenty":-70.379394,"median":-39.220244,"eighty":-7.806798,"marketCap":197264409},{"date":"2024-05-17","current":-48.426621,"twenty":-71.185147,"median":-39.390029,"eighty":-8.309389,"marketCap":201061130},{"date":"2024-05-24","current":-37.632017,"twenty":-70.941929,"median":-39.252477,"eighty":-8.383702,"marketCap":156243317},{"date":"2024-05-31","current":-37.651896,"twenty":-70.600999,"median":-39.231253,"eighty":-8.399347,"marketCap":156325854},{"date":"2024-06-07","current":-38.148885,"twenty":-69.492975,"median":-39.142864,"eighty":-8.458016,"marketCap":158389289},{"date":"2024-06-14","current":-37.791053,"twenty":-68.677874,"median":-39.132924,"eighty":-8.477572,"marketCap":156903616},{"date":"2024-06-21","current":-39.600094,"twenty":-68.284435,"median":-39.132924,"eighty":-8.688778,"marketCap":164414520},{"date":"2024-06-28","current":-34.033815,"twenty":-67.93606,"median":-39.122984,"eighty":-8.944963,"marketCap":141304045},{"date":"2024-07-05","current":-30.813326,"twenty":-67.00636,"median":-39.083225,"eighty":-9.025143,"marketCap":127932985},{"date":"2024-07-12","current":-31.707906,"twenty":-66.374913,"median":-38.90211,"eighty":-9.138568,"marketCap":131647168},{"date":"2024-07-19","current":-32.304293,"twenty":-66.254136,"median":-38.668445,"eighty":-9.459288,"marketCap":134123291},{"date":"2024-07-26","current":-27.89103,"twenty":-66.009803,"median":-38.625997,"eighty":-9.678316,"marketCap":115799986},{"date":"2024-08-02","current":-21.131978,"twenty":-65.799563,"median":-38.413768,"eighty":-9.715473,"marketCap":87737266},{"date":"2024-08-09","current":-18.460659,"twenty":-64.992694,"median":-38.255401,"eighty":-10.106595,"marketCap":93102198},{"date":"2024-08-16","current":-29.88401,"twenty":-63.82037,"median":-38.148885,"eighty":-10.558342,"marketCap":150713310},{"date":"2024-08-23","current":-26.709039,"twenty":-63.123956,"median":-37.878225,"eighty":-10.740213,"marketCap":134701053},{"date":"2024-08-30","current":-30.47318,"twenty":-62.875574,"median":-37.791053,"eighty":-10.88395,"marketCap":153684657},{"date":"2024-09-06","current":-23.484969,"twenty":-62.310952,"median":-37.632017,"eighty":-13.958048,"marketCap":118441183},{"date":"2024-09-13","current":-28.656572,"twenty":-61.520597,"median":-37.39506,"eighty":-19.017097,"marketCap":144523004},{"date":"2024-09-20","current":-27.560062,"twenty":-60.889782,"median":-37.352614,"eighty":-20.363844,"marketCap":138992998},{"date":"2024-09-27","current":-24.761504,"twenty":-59.992238,"median":-37.044217,"eighty":-21.696558,"marketCap":124879101},{"date":"2024-10-04","current":-23.484969,"twenty":-59.885067,"median":-36.618159,"eighty":-21.737099,"marketCap":118441183},{"date":"2024-10-11","current":-22.093874,"twenty":-59.702244,"median":-36.256014,"eighty":-21.195966,"marketCap":111425503},{"date":"2024-10-18","current":-23.40314,"twenty":-59.499033,"median":-36.121676,"eighty":-21.422875,"marketCap":118028496},{"date":"2024-10-25","current":-22.42119,"twenty":-59.246339,"median":-35.506843,"eighty":-21.041389,"marketCap":113076251},{"date":"2024-11-01","current":-20.964631,"twenty":-58.949205,"median":-34.593614,"eighty":-21.041389,"marketCap":105730422},{"date":"2024-11-08","current":-20.522754,"twenty":-58.467774,"median":-33.995368,"eighty":-20.604583,"marketCap":103501912},{"date":"2024-11-15","current":-7.440484,"twenty":-58.205855,"median":-32.960319,"eighty":-20.319817,"marketCap":88892790},{"date":"2024-11-22","current":-6.632186,"twenty":-57.268349,"median":-31.876883,"eighty":-19.75356,"marketCap":79235913},{"date":"2024-11-29","current":-7.461209,"twenty":-55.646905,"median":-31.638328,"eighty":-10.811593,"marketCap":89140402},{"date":"2024-12-06","current":-8.228056,"twenty":-54.314096,"median":-31.509111,"eighty":-9.711562,"marketCap":98302055},{"date":"2024-12-13","current":-1.31262,"twenty":-52.81792,"median":-30.753634,"eighty":-9.005587,"marketCap":15682107},{"date":"2024-12-20","current":-1.540602,"twenty":-48.999152,"median":-30.455494,"eighty":-8.411081,"marketCap":18405842},{"date":"2024-12-27","current":-1.658046,"twenty":-48.426621,"median":-29.978384,"eighty":-8.228056,"marketCap":19808978},{"date":"2025-01-03","current":-1.609687,"twenty":-47.997222,"median":-29.785815,"eighty":-7.657262,"marketCap":19231216},{"date":"2025-01-10","current":-1.457699,"twenty":-47.144687,"median":-29.245398,"eighty":-7.393795,"marketCap":17415393},{"date":"2025-01-17","current":-1.457699,"twenty":-44.916349,"median":-28.653863,"eighty":-7.183487,"marketCap":17415393},{"date":"2025-01-24","current":-1.59587,"twenty":-43.761983,"median":-28.638191,"eighty":-7.010773,"marketCap":19066141},{"date":"2025-01-31","current":-1.561327,"twenty":-43.745005,"median":-28.566935,"eighty":-6.6764,"marketCap":18653454},{"date":"2025-02-07","current":-1.526784,"twenty":-43.24863,"median":-27.889204,"eighty":-6.348881,"marketCap":18240767},{"date":"2025-02-14","current":-1.609687,"twenty":-42.503822,"median":-27.789183,"eighty":-5.849231,"marketCap":19231216},{"date":"2025-02-21","current":-1.575144,"twenty":-42.386727,"median":-27.612716,"eighty":-5.677137,"marketCap":18818529},{"date":"2025-02-28","current":-1.54751,"twenty":-42.123561,"median":-27.159099,"eighty":-5.235169,"marketCap":18488379},{"date":"2025-03-07","current":-1.526784,"twenty":-42.013202,"median":-26.709039,"eighty":-5.079111,"marketCap":18240767},{"date":"2025-03-14","current":-4.449091,"twenty":-41.962266,"median":-26.52242,"eighty":-4.902715,"marketCap":53154092},{"date":"2025-03-21","current":-7.633919,"twenty":-41.885863,"median":-26.463551,"eighty":-4.893488,"marketCap":124361854},{"date":"2025-03-28","current":-5.06435,"twenty":-41.817949,"median":-26.005308,"eighty":-4.799924,"marketCap":82501776},{"date":"2025-04-04","current":-5.919092,"twenty":-41.665143,"median":-25.710723,"eighty":-4.841604,"marketCap":96426126},{"date":"2025-04-11","current":-4.538149,"twenty":-41.597229,"median":-25.473418,"eighty":-4.783424,"marketCap":73929597},{"date":"2025-04-17","current":-5.235298,"twenty":-41.597229,"median":-25.219748,"eighty":-4.791246,"marketCap":85286646},{"date":"2025-04-25","current":-4.61561,"twenty":-41.512337,"median":-24.761504,"eighty":-4.727795,"marketCap":75191492},{"date":"2025-05-02","current":-5.475694,"twenty":-41.298141,"median":-24.40964,"eighty":-4.781468,"marketCap":89202869},{"date":"2025-05-09","current":-4.535478,"twenty":-40.703923,"median":-23.894115,"eighty":-4.754506,"marketCap":73886084},{"date":"2025-05-16","current":-4.092569,"twenty":-40.111614,"median":-23.509518,"eighty":-4.701084,"marketCap":76409872},{"date":"2025-05-23","current":-3.924764,"twenty":-39.899383,"median":-23.40314,"eighty":-4.546794,"marketCap":73276893},{"date":"2025-05-30","current":-3.631106,"twenty":-39.899383,"median":-22.993995,"eighty":-4.534221,"marketCap":67794181},{"date":"2025-06-06","current":-3.514575,"twenty":-39.885461,"median":-22.735979,"eighty":-4.503786,"marketCap":65618501},{"date":"2025-06-13","current":-3.551865,"twenty":-39.7837,"median":-22.503019,"eighty":-4.258784,"marketCap":66314718},{"date":"2025-06-20","current":-3.258207,"twenty":-39.75913,"median":-22.404825,"eighty":-4.158521,"marketCap":60832005},{"date":"2025-06-27","current":-3.311811,"twenty":-39.663708,"median":-22.077508,"eighty":-4.077653,"marketCap":61832818},{"date":"2025-07-03","current":-2.633601,"twenty":-39.550025,"median":-21.823837,"eighty":-3.980044,"marketCap":49170362},{"date":"2025-07-11","current":-3.360754,"twenty":-39.440965,"median":-21.455606,"eighty":-3.896797,"marketCap":62746603},{"date":"2025-07-18","current":-3.528559,"twenty":-39.386585,"median":-21.072854,"eighty":-3.646022,"marketCap":65879582},{"date":"2025-07-25","current":-3.752298,"twenty":-39.349611,"median":-20.964631,"eighty":-3.646022,"marketCap":70056887},{"date":"2025-08-01","current":-3.845523,"twenty":-39.3019,"median":-20.547303,"eighty":-3.685176,"marketCap":71797431},{"date":"2025-08-08","current":-4.353598,"twenty":-39.293948,"median":-20.408193,"eighty":-3.727127,"marketCap":81283395},{"date":"2025-08-15","current":-4.169718,"twenty":-39.274289,"median":-19.933584,"eighty":-3.76778,"marketCap":94285206},{"date":"2025-08-22","current":-3.772796,"twenty":-39.254519,"median":-19.688096,"eighty":-3.760497,"marketCap":85310069},{"date":"2025-08-29","current":-3.813716,"twenty":-39.233455,"median":-10.865861,"eighty":-3.760497,"marketCap":86235341},{"date":"2025-09-05","current":-4.177901,"twenty":-39.220244,"median":-10.526074,"eighty":-3.773614,"marketCap":94470260},{"date":"2025-09-12","current":-3.764612,"twenty":-39.204768,"median":-9.709606,"eighty":-3.773614,"marketCap":85125014},{"date":"2025-09-19","current":-3.314496,"twenty":-39.138888,"median":-9.122923,"eighty":-3.737606,"marketCap":74947023},{"date":"2025-09-26","current":-3.199921,"twenty":-39.116968,"median":-8.741579,"eighty":-3.623336,"marketCap":72356262},{"date":"2025-10-03","current":-3.34314,"twenty":-39.09097,"median":-8.428681,"eighty":-3.551865,"marketCap":75594714},{"date":"2025-10-10","current":-3.494542,"twenty":-39.075273,"median":-8.291789,"eighty":-3.534152,"marketCap":79018220},{"date":"2025-10-17","current":-3.109897,"twenty":-39.027886,"median":-7.962078,"eighty":-3.498549,"marketCap":70320664},{"date":"2025-10-24","current":-2.897115,"twenty":-38.940184,"median":-7.633919,"eighty":-3.482878,"marketCap":65509250},{"date":"2025-10-30","current":-2.815275,"twenty":-38.838654,"median":-7.461209,"eighty":-3.38406,"marketCap":63658706}],"updateTime":1761969555745},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CRVO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2578495458","title":"CervoMed appoints Quigley to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2578495458","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578495458?lang=en_us&edition=fundamental","pubTime":"2025-10-28 20:31","pubTimestamp":1761654711,"startTime":"0","endTime":"0","summary":"CervoMed (CRVO) announced the appointment of David Quigley to its Board of Directors. Quigley is a seasoned executive and former Senior Partner at ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomed-appoints-quigley-to-board-of-directors-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomed-appoints-quigley-to-board-of-directors-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2578959367","title":"Press Release: CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley","url":"https://stock-news.laohu8.com/highlight/detail?id=2578959367","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578959367?lang=en_us&edition=fundamental","pubTime":"2025-10-28 20:00","pubTimestamp":1761652800,"startTime":"0","endTime":"0","summary":"Mr. Quigley most recently led McKinsey & Company's Private Capital practice and previously led various Life Sciences practices at the firm. Appointment adds deep business strategy, transactional, and commercial expertise as CervoMed prepares for Phase 3 and commercialization planning. \"It is a pleasure to welcome David to our Board,\" said Joshua Boger, Ph.D., Chair of the CervoMed Board of Directors and founder of Vertex Pharmaceuticals. \"His strategic insight and commercial acumen are ideally suited to support CervoMed's mission as we advance neflamapimod toward transformative milestones. We look forward to leveraging his extensive business strategy and financial insights, as well as his broad network of relationships in the pharmaceutical and private equity industries, to drive progress for patients and value for our stockholders.\". DLB is the second most common progressive dementia after Alzheimer's di","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0240878834.USD","CRVO","LU0348723411.USD","LU0240877869.USD","LU0345774391.USD","LU0345774631.USD","DLB","BK4097","LU0205193047.USD","LU0205194284.USD","BK4139"],"gpt_icon":0},{"id":"2578629101","title":"CervoMed Showcases Neflamapimod’s Phase 2b Progress for Dementia with Lewy Bodies","url":"https://stock-news.laohu8.com/highlight/detail?id=2578629101","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578629101?lang=en_us&edition=fundamental","pubTime":"2025-10-28 01:06","pubTimestamp":1761584791,"startTime":"0","endTime":"0","summary":"Cervomed Inc. has announced that neflamapimod, its investigational oral therapy, has achieved Phase 2b clinical proof-of-concept and is now progressing into a 24-week pivotal study for dementia with Lewy bodies . The company highlights that DLB represents a significant and underserved global market. Preclinical studies demonstrated that neflamapimod reversed neurodegenerative processes in animal models, including improvements in cholinergic neuron function and behavioral outcomes. In the 16-week, placebo-controlled Phase 2a clinical trial  involving 91 patients with DLB, neflamapimod significantly improved dementia severity and gait compared to placebo and reduced plasma biomarkers associated with neurodegeneration. The therapy showed a well-defined safety profile, with clinical safety data from over 700 volunteers and patients. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelli","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nNDL1y4LNb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2577331110","title":"CervoMed Releases Investor Presentation on Website","url":"https://stock-news.laohu8.com/highlight/detail?id=2577331110","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577331110?lang=en_us&edition=fundamental","pubTime":"2025-10-23 04:36","pubTimestamp":1761165384,"startTime":"0","endTime":"0","summary":"CervoMed ( ($CRVO) ) has shared an announcement. CervoMed Inc. has made available a presentation on its website, detailing its business, clinical s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cervomed-releases-investor-presentation-on-website?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cervomed-releases-investor-presentation-on-website?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2576851054","title":"CervoMed to Present at the Emerging Growth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2576851054","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576851054?lang=en_us&edition=fundamental","pubTime":"2025-10-20 20:00","pubTimestamp":1760961600,"startTime":"0","endTime":"0","summary":"BOSTON, Oct.  20, 2025  (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), toda","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/20/3169277/0/en/CervoMed-to-Present-at-the-Emerging-Growth-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"gpt_icon":0},{"id":"2576037743","title":"CervoMed’s Strategic Phase 3 Trial Plans and Financial Outlook Justify Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2576037743","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576037743?lang=en_us&edition=fundamental","pubTime":"2025-10-17 20:15","pubTimestamp":1760703359,"startTime":"0","endTime":"0","summary":"Analyst Soumit Roy of JonesTrading maintained a Buy rating on CervoMed, retaining the price target of $20.00. Soumit Roy has given his Buy rating d...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cervomeds-strategic-phase-3-trial-plans-and-financial-outlook-justify-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cervomeds-strategic-phase-3-trial-plans-and-financial-outlook-justify-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"gpt_icon":0},{"id":"2574970677","title":"CervoMed Unveils Promising Phase 2b Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2574970677","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574970677?lang=en_us&edition=fundamental","pubTime":"2025-10-09 04:59","pubTimestamp":1759957196,"startTime":"0","endTime":"0","summary":"The latest update is out from CervoMed ( ($CRVO) ). On October 8, 2025, CervoMed Inc. announced new data from its Phase 2b RewinD-LB trial, highlig...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cervomed-unveils-promising-phase-2b-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cervomed-unveils-promising-phase-2b-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO","BK4139"],"gpt_icon":0},{"id":"2574972322","title":"CervoMed Inc. Files Initial Statement of Beneficial Ownership for Chief Commercial and Business Officer Matthew Winton","url":"https://stock-news.laohu8.com/highlight/detail?id=2574972322","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574972322?lang=en_us&edition=fundamental","pubTime":"2025-10-09 04:07","pubTimestamp":1759954047,"startTime":"0","endTime":"0","summary":"Cervomed Inc. has filed an initial statement of beneficial ownership  with the SEC. The filing lists Matthew Winton as the beneficial owner, who serves as the company's Chief Commercial and Business Officer. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nNDLbbk7BX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2574470975","title":"BUZZ-U.S. STOCKS ON THE MOVE-Datadog, First Majestic, Best Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2574470975","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574470975?lang=en_us&edition=fundamental","pubTime":"2025-10-09 01:39","pubTimestamp":1759945145,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Datadog, First Majestic, Best BuyEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nL6N3VP0FJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JEF","CTVA","PSX","LU0203347892.USD","EFX","ELF","NEM","LU2023250843.SGD","SMTC","LU0251142724.SGD","LU1917777945.USD","CFLT","CRVO","BBY","CHRW","URI","LU0130102774.USD","DAL","CVS","HOWL","BLD","ARCB","LU1559883803.SGD","ATON","HL","F","DDOG","HOTH","WERN","PEP","LYV","FRPT","ZBIO","CAT","FDX","SLB","BK4548","CDE","SCCO","NEXT","CMI","BK4022"],"gpt_icon":1},{"id":"2574978999","title":"CervoMed’s Strategic Advancements in Clinical Trials Justify Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2574978999","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574978999?lang=en_us&edition=fundamental","pubTime":"2025-10-09 00:15","pubTimestamp":1759940115,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Soumit Roy maintained a Buy rating on CervoMed today and set a price target of $20.00. Soumit Roy has given his Buy rating due...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cervomeds-strategic-advancements-in-clinical-trials-justify-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cervomeds-strategic-advancements-in-clinical-trials-justify-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"gpt_icon":0},{"id":"2573295139","title":"CervoMed Inc Shares Rise 3.5% After Dementia Drug Shows Promise in Mid-Stage Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2573295139","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573295139?lang=en_us&edition=fundamental","pubTime":"2025-10-08 21:31","pubTimestamp":1759930289,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nFWN3VP1V5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRVO","BK4139"],"gpt_icon":0},{"id":"2573926683","title":"BUZZ-U.S. STOCKS ON THE MOVE-Ford Motor, CVS Health, Phillips 66","url":"https://stock-news.laohu8.com/highlight/detail?id=2573926683","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573926683?lang=en_us&edition=fundamental","pubTime":"2025-10-08 21:09","pubTimestamp":1759928989,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Ford Motor, CVS Health, Phillips 66Eikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nL6N3VP0EZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["2NVD.UK","NVDX","AU","NVDS.UK","LU1941712264.USD","LU2456880835.USD","LU0061474705.USD","SNVD.UK","VZ","FRPT","3NVD.UK","LYV","CRVO","LU0128526141.USD","SG9999015358.SGD","WERN","NVD2.UK","NVD","LU0466842654.USD","LU0788109121.HKD","LU0345768740.USD","F","NEM","FDX","NVIW.SI","NVDY","NVD3.UK","NVDD","NVDU","HOTH","CDE","IE00BHPRN162.USD","ZBIO","HOWL","EVR","PSX","NVDS","CFLT","ESPR","CVS","SLB","HL"],"gpt_icon":1},{"id":"2573928525","title":"BUZZ-CervoMed rises after dementia drug shows promise in mid-stage study","url":"https://stock-news.laohu8.com/highlight/detail?id=2573928525","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573928525?lang=en_us&edition=fundamental","pubTime":"2025-10-08 19:55","pubTimestamp":1759924556,"startTime":"0","endTime":"0","summary":"BUZZ-CervoMed rises after dementia drug shows promise in mid-stage study ** U.S. drug developer CervoMed CRVO.O shares rise 12% to $9.55 in premarket trading** Co said its experimental drug neflamapimod showed promising results in a mid-stage trial for dementia with Lewy bodies, a common age-related dementia** Patients taking neflamapimod had significant improvements in memory and daily function versus placebo - CRVO ** CRVO says benefits were most notable in patients unlikely to have Alzheimer's alongside Lewy body dementia** The results helped CRVO refine plans for a late-stage trial; co expects FDA feedback on its late-stage design by year-end.** Up to last close, stock up ~265%  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nL3N3VP0NP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2573947619","title":"CervoMed Inc - Anticipates FDA Feedback on Phase 3 Trial in Q4 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2573947619","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573947619?lang=en_us&edition=fundamental","pubTime":"2025-10-08 19:00","pubTimestamp":1759921200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nTUA56LZQP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRVO","BK4139"],"gpt_icon":0},{"id":"2573494761","title":"CervoMed Inc - Significant Reduction in Plasma Gfap Levels Correlated to Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2573494761","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573494761?lang=en_us&edition=fundamental","pubTime":"2025-10-08 19:00","pubTimestamp":1759921200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nTUA56LZQP:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2573476169","title":"CervoMed Inc - Significant Improvement in Cdr-SB in Low Ad Co-Pathology Participants","url":"https://stock-news.laohu8.com/highlight/detail?id=2573476169","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573476169?lang=en_us&edition=fundamental","pubTime":"2025-10-08 19:00","pubTimestamp":1759921200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nTUA56LZQP:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2573794744","title":"CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies","url":"https://stock-news.laohu8.com/highlight/detail?id=2573794744","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573794744?lang=en_us&edition=fundamental","pubTime":"2025-10-08 19:00","pubTimestamp":1759921200,"startTime":"0","endTime":"0","summary":"Significant improvement relative to placebo on primary outcome measure, change in Clinical Dementia Rating Sum of Boxes (CDR-SB), demonstrated in a within-subject analysis in participants with low lik","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/08/3163184/0/en/CervoMed-Announces-New-Data-from-Phase-2b-Trial-Demonstrating-Neflamapimod-s-Potential-as-a-Treatment-for-Dementia-with-Lewy-Bodies.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"gpt_icon":0},{"id":"2573950310","title":"CervoMed appoints Matthew Winton as chief commercial, business officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2573950310","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573950310?lang=en_us&edition=fundamental","pubTime":"2025-10-07 20:35","pubTimestamp":1759840509,"startTime":"0","endTime":"0","summary":"CervoMed (CRVO) announced the appointment of Matthew Winton, Ph.D., as Chief Commercial and Business Officer. Before joining CervoMed, Dr. Winton s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomed-appoints-matthew-winton-as-chief-commercial-business-officer-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomed-appoints-matthew-winton-as-chief-commercial-business-officer-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2573957574","title":"BRIEF-Cervomed Appoints Matthew Winton, Ph.D., As Chief Commercial And Business Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2573957574","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573957574?lang=en_us&edition=fundamental","pubTime":"2025-10-07 20:18","pubTimestamp":1759839512,"startTime":"0","endTime":"0","summary":"BRIEF-Cervomed Appoints Matthew Winton, Ph.D., As Chief Commercial And Business OfficerOct 7 (Reuters) - CervoMed Inc CRVO.O:CERVOMED APPOINTS MATTHEW WINTON, PH.D., AS CHIEF COMMERCIAL AND BUSINESS O","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nTUA15P6RH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2573522809","title":"Press Release: CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2573522809","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573522809?lang=en_us&edition=fundamental","pubTime":"2025-10-07 20:00","pubTimestamp":1759838400,"startTime":"0","endTime":"0","summary":"BOSTON, Oct. 07, 2025  -- CervoMed Inc. , a clinical stage company focused on developing treatments for age-related neurologic disorders , today announced the appointment of Matthew Winton, Ph.D., as Chief Commercial and Business Officer. Dr. Winton joins CervoMed with nearly two decades of experience in the global biotechnology industry, leading organizations through scientific breakthroughs, growth and innovation, and market transformation.\"It is a pleasure to welcome Matthew, an experienced and proven leader and organization builder,\" said John Alam, M.D., Chief Executive Officer of CervoMed. \"This appointment comes at a pivotal time for CervoMed as we advance into late-stage Phase 3 development. Matthew's deep commercial expertise and proven success in establishing patient-focused healthcare franchises in the CNS space, will be critical as we strategically advance the business and prepare to bring neflamapimod to patients battling dementia with Lewy bodies .\". On October 6, 2025, C","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4604","BK4217","LU0240878834.USD","LU0345774391.USD","LU0205194284.USD","LU0240877869.USD","SMA","CRVO","03160","BK4555","LU0348723411.USD","BK4097","DLB","BK4099","BK4588","TM","LU0345774631.USD","LU0205193047.USD","BK4585"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":51,"code":"91000000","status":"200"}]}}